5,148 Shares in Insmed, Inc. $INSM Purchased by Pinkerton Wealth LLC

Pinkerton Wealth LLC acquired a new position in shares of Insmed, Inc. (NASDAQ:INSM) during the 4th quarter, Holdings Channel reports. The fund acquired 5,148 shares of the biopharmaceutical company’s stock, valued at approximately $896,000.

Several other institutional investors have also modified their holdings of the stock. CIBC Private Wealth Group LLC boosted its stake in Insmed by 42.1% during the third quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 53 shares during the period. CoreCap Advisors LLC purchased a new stake in shares of Insmed during the fourth quarter valued at $27,000. SBI Securities Co. Ltd. boosted its stake in shares of Insmed by 404.9% during the third quarter. SBI Securities Co. Ltd. now owns 207 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 166 shares during the period. GraniteShares Advisors LLC purchased a new stake in shares of Insmed during the fourth quarter valued at $30,000. Finally, Whittier Trust Co. of Nevada Inc. raised its holdings in shares of Insmed by 169.7% in the third quarter. Whittier Trust Co. of Nevada Inc. now owns 240 shares of the biopharmaceutical company’s stock valued at $38,000 after acquiring an additional 151 shares in the last quarter.

Insider Activity

In other news, insider Michael Alexander Smith sold 19,638 shares of the stock in a transaction that occurred on Monday, March 30th. The stock was sold at an average price of $150.98, for a total transaction of $2,964,945.24. Following the transaction, the insider owned 51,871 shares in the company, valued at $7,831,483.58. This trade represents a 27.46% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, COO Roger Adsett sold 88,060 shares of the stock in a transaction that occurred on Wednesday, April 1st. The shares were sold at an average price of $164.63, for a total value of $14,497,317.80. Following the transaction, the chief operating officer owned 106,810 shares in the company, valued at $17,584,130.30. This trade represents a 45.19% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 150,494 shares of company stock worth $23,846,784 in the last quarter. Corporate insiders own 2.10% of the company’s stock.

Analyst Ratings Changes

Several research firms recently weighed in on INSM. Bank of America lifted their price objective on Insmed from $211.00 to $213.00 and gave the company a “buy” rating in a report on Tuesday, March 24th. Raymond James Financial initiated coverage on shares of Insmed in a report on Friday, April 10th. They set an “outperform” rating and a $200.00 price objective on the stock. Leerink Partners upped their price objective on shares of Insmed from $210.00 to $215.00 and gave the company an “outperform” rating in a report on Tuesday, March 24th. Truist Financial cut their price target on shares of Insmed from $205.00 to $185.00 and set a “buy” rating on the stock in a report on Wednesday, May 13th. Finally, Mizuho increased their price target on shares of Insmed from $204.00 to $206.00 and gave the stock an “outperform” rating in a report on Wednesday, March 25th. One analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $210.95.

Insmed Trading Up 0.5%

Insmed stock opened at $107.91 on Thursday. The company has a current ratio of 4.47, a quick ratio of 4.10 and a debt-to-equity ratio of 0.80. Insmed, Inc. has a 12 month low of $64.85 and a 12 month high of $212.75. The stock’s 50 day simple moving average is $139.24 and its two-hundred day simple moving average is $161.82. The firm has a market cap of $23.39 billion, a PE ratio of -18.77 and a beta of 0.89.

Insmed (NASDAQ:INSM) last released its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($0.76) EPS for the quarter, topping the consensus estimate of ($0.90) by $0.14. Insmed had a negative return on equity of 130.11% and a negative net margin of 144.44%.The business had revenue of $305.96 million for the quarter, compared to analyst estimates of $300.81 million. During the same quarter in the prior year, the firm posted ($1.42) EPS. The business’s quarterly revenue was up 229.7% compared to the same quarter last year. Analysts anticipate that Insmed, Inc. will post -2.52 earnings per share for the current year.

Insmed Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.